Celery Seed

Phase 2Small molecule

UUniversity of Guadalajara

Celery Seed is one of 43 small molecule programs targeting Metabolic Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic SyndromeActive, not recruiting

Metabolic SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

190 competitors in Metabolic Syndrome

#DrugCompanyPhaseTrials

Precose

Bayer

Phase 3

1 2

Zetia

OOrganon and Co

Phase 3

3 3

Jardiance

Boehringer Ingelheim

Phase 3

2 4

Topamax

WWim Janssens

Phase 3

1 5

Kineret

SSwedish Orphan Biovitrum

Phase 3

1 6

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 7

Benicar

CCosette Pharmaceuticals, Inc.

Phase 3

1 8

Pioglitazone and Insulin

Takeda

Phase 3

1 9

Nebido

Bayer

Phase 3

1 10

Obicetrapib

NNewAmsterdam Pharma

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metabolic Syndrome1 trial

Effect of Celery Seed on the Components of Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion

Recruiting·UUniversity of Guadalajara·Phase 2·NCT06061926·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Celery Seed. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Celery Seed compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Celery Seed. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Guadalajara company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Guadalajara

Celery Seed

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metabolic Syndrome1 trial

References

Drug Info

Quick Facts

Related News